AURORA-1: Voclosporin Efficacy in Lupus Nephritis

Save

Lancet has published the results of the AURORA-1 trial, wherein the calcineurin inhibitor, voclosporin, was tested in a placebo controlled trial of lupus nephritis and shown to be effective at inducing a complete renal response.

Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus

Save

Petri and colleagues have published that measuring hydroxychloroquine (HCQ) blood levels can be useful in systemic lupus erythematosus (SLE), as low levels are associated with an increased thrombotic risk in SLE.

RheumNow Podcast – Falling or Falling in Love?

Save

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Childhood Lupus May Hamper Adult Careers

Save

Long-term outcomes of kids with childhood-onset systemic lupus erythematosus (cSLE) are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood.

Autoimmune Thyroid Disease in Women

Save

JAMA has posted an insights article reviewing autoimmune thyroid disease in women. Thyroid autoimmunity has a higher prevalence in women and with increasing age.

Similar to many autoimmune disorders, thyroid disease is more common in women than in men.

Higher Cardiovascular Risks with Systemic Lupus Erythematosus

Save

The Journal of the American College of Cardiology has published the results of a study showing that patients with systemic lupus erythematosus (SLE) have an increased risk of heart failure (HF) and other long-term cardiovascular outcomes. 

Lupus Activity Affects Mortality

Save

Each one-unit increase on a disease activity score during the first year after enrollment into a systemic lupus erythematosus (SLE) cohort was associated with a significant increased risk for death and organ damage during subsequent follow-up, researchers reported.

RheumNow Podcast – Coconspirators: RA and Lung Disease

Save

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Combination Biologics

Save

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Autoimmune Risk of Death Up during COVID

Save

A population-based study in the UK shows that patients with rare autoimmune rheumatic diseases (RAIRD) were 44% more likely to die during the 2020 COVID-19 pandemic (March - April) compared to either the general population or their pre-COVID risk.

DMARD Dropouts During COVID-19

Save

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.

Rheumatology Care Derailed by COVID-19

Save

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Save

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.

MDA-5 Antibodies and Juvenile Dermatomyositis

Save

A multicentre, retrospective study examined MSA profiles (by immunoprecipitation) from 96 juvenile idiopathic inflammatory myopathies (JIIM) at nine pediatric rheumatology centres in Japan. MSA were found in 85 of 96 cases with over 90% of patients having one of the following three MSA types:

Rheumatic Patients Are at Risk for COVID Death

Save

Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Save

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.